Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Maxcyte Inc
(NQ:
MXCT
)
4.140
+0.040 (+0.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Maxcyte Inc
< Previous
1
2
3
4
Next >
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
August 06, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
July 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
May 29, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Earnings Preview
March 11, 2024
Via
Benzinga
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
May 22, 2024
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T...
From
MaxCyte, Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 08, 2024
Via
Benzinga
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
May 08, 2024
Via
Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 08, 2024
Via
Benzinga
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
May 07, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
April 10, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 02, 2024
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs
From
MaxCyte, Inc
Via
GlobeNewswire
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
March 20, 2024
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.
Via
Benzinga
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
March 20, 2024
U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
March 13, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 12, 2024
Via
Benzinga
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
March 12, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
March 04, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
February 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For March 12, 2024
March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
Via
Benzinga
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
January 30, 2024
Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
January 23, 2024
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer...
From
MaxCyte, Inc
Via
GlobeNewswire
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
January 09, 2024
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Cell Engineering Company MaxCyte Shares Are Up Today
January 09, 2024
MaxCyte Inc (NASDAQ: MXCT) shares are trading higher by over 9% after the company disclosed strong preliminary Q4 and full-year
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 08, 2024
Via
Benzinga
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
January 08, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
January 03, 2024
Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases.
From
MaxCyte, Inc; Lion TCR
Via
GlobeNewswire
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
January 02, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.